Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Olympus (OLYMY)
OTHER OTC:OLYMY
Holding OLYMY?
Track your performance easily
Earnings Data
Report Date
Feb 07, 2025TBA Not Confirmed
Period Ending
2025 (Q3)Consensus EPS Forecast
0.23Last Year’s EPS
0.12Same Quarter Last Year
Based on 0 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 06, 2018
|% Change Since: -12.31%
|Next Earnings Date:Aug 07, 2018
Earnings Call Sentiment|Neutral
The earnings call presented a balanced view of strong revenue growth and progress in technological advancements, such as AI endoscopy devices and the Elevate program. However, challenges remain, particularly in the Chinese market and leadership stability following the CEO scandal.Company Guidance
The earnings call for 7733.T concerning Q2 fiscal year 2025 highlighted various metrics and strategic updates. Revenue grew by 10% year-over-year, reaching JPY 474 billion, driven by strong performance in North America with a 24% increase, despite challenges in China. Adjusted operating profit rose by 28% year-over-year to JPY 85.1 billion, with an adjusted operating margin improving to 17.9%. The company continues to address regulatory commitments under the Elevate program, with over 95% of commitments to the FDA completed. Olympus remains focused on its long-term growth strategy, supported by recent regulatory approvals for cloud-based AI endoscopy devices in the U.S. and Europe. The fiscal year 2025 forecast remains unchanged, with ongoing efforts to respond to changing market conditions and enhance product offerings.Revenue Growth
Consolidated revenue increased by 10% year-over-year to JPY 474 billion, driven by strong performance in North America with 24% growth.
Approval of AI Endoscopy Devices
Received clearance and approval for cloud-based AI endoscopy devices in the U.S. and Europe, marking a significant milestone for future growth.
Improved Operating Profit
Operating profit increased significantly to JPY 70.5 billion, with adjusted operating profit up by 28% year-on-year to JPY 85.1 billion.
Elevate Program Progress
Progress on the Elevate program with over 95% of commitments to the FDA completed, indicating strong compliance and quality improvements.
New CPT Code for ITM Procedure
The new CPT code and reimbursement rates will enhance the economic viability of the ITM procedure, increasing access for patients.
---
OLYMY Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
OLYMY Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 08, 2024 | $17.63 | $17.45 | -1.02% |
| Aug 07, 2024 | $16.11 | $16.45 | +2.11% |
| May 10, 2024 | $14.67 | $14.68 | +0.07% |
| Feb 14, 2024 | $14.16 | $13.94 | -1.55% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Olympus (OLYMY) report earnings?
Olympus (OLYMY) is schdueled to report earning on Feb 07, 2025, TBA Not Confirmed.
What is Olympus (OLYMY) earnings time?
Olympus (OLYMY) earnings time is at Feb 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is OLYMY EPS forecast?
OLYMY EPS forecast for the fiscal quarter 2025 (Q3) is 0.23.
---